Newsgather

clinical trials

Steady9 stories8 sourcesLast updated: 6/2/2026

Latest Stories

Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’
NEWS
5/5/2026

Slow Alzheimer’s diagnoses ‘mean UK patients missing out on experimental treatments’

Alzheimer’s Research UK says patients at risk of being left behind as lack of formal or accurate diagnoses closes door to trialsPeople with Alzheimer’s disease are missing out on experimental treatments because they are not diagnosed early or accurately enough to be enrolled in clinical trials, a UK charity has said.Trials of Alzheimer’s drugs reached a record high this year, according to data published on Tuesday, but Alzheimer’s Research UK said too few UK patients were taking part because their diagnoses were delayed or were not specific enough. Continue reading...

G
Guardian UK
Hong Kong researchers develop ‘world-first’ nasal spray for rapid stroke aid
NEWS
5/5/2026

Hong Kong researchers develop ‘world-first’ nasal spray for rapid stroke aid

Researchers at the University of Hong Kong (HKU) say they have developed a world-first nasal spray that delivers neurotherapeutic powder directly to the brain as first aid for ischemic stroke patients, with clinical trials expected by 2030. The treatment is intended for initial use by paramedics, before being rolled out to high-risk groups in care facilities and eventually the general public through pharmacies. It was developed by the Li Ka Shing Faculty of Medicine at HKU and the university’s...

S
SCMP Economy
Trump Signs Executive Order to Accelerate Psychedelics Research, Sparking Stock Rally
Developing
Politics·4/20/2026AI summary

Trump Signs Executive Order to Accelerate Psychedelics Research, Sparking Stock Rally

President Donald Trump signed an executive order on Saturday aimed at accelerating psychedelics research, directing agencies to expand clinical trials and Right to Try access for psilocybin, MDMA and ibogaine. The order leaves drug scheduling unchanged and comes amid stalled cannabis rescheduling efforts, raising questions about whether psychedelics will face similar federal delays. Psychedelic stocks rallied significantly following the announcement, with AtaiBeckley jumping roughly 25%.

C
CNBC US Markets